Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age

T. Michael O'Shea, Jamanadas M. Kothadia, Kurt L. Klinepeter, Donald J. Goldstein, Barbara G. Jackson, R. Grey Weaver and III‡; and Robert G. Dillard
Pediatrics July 1999, 104 (1) 15-21; DOI: https://doi.org/10.1542/peds.104.1.15
T. Michael O'Shea
From the Departments of *Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamanadas M. Kothadia
From the Departments of *Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt L. Klinepeter
From the Departments of *Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald J. Goldstein
From the Departments of *Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara G. Jackson
From the Departments of *Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Grey Weaver
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
III‡; and Robert G. Dillard
From the Departments of *Pediatrics and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Abstract

Objective. Ventilator-dependent preterm infants are often treated with a prolonged tapering course of dexamethasone to decrease the risk and severity of chronic lung disease. The objective of this study was to assess the effect of this therapy on developmental outcome at 1 year of age.

Methods. Study participants were 118 very low birth weight infants who, at 15 to 25 days of life, were not weaning from assisted ventilation and were then enrolled in a randomized, placebo-controlled, double-blind trial of a 42-day tapering course of dexamethasone. Infants were examined at 1 year of age, adjusted for prematurity, by a pediatrician and a child psychologist. A physical and neurologic examination was performed, and the Bayley Scales of Infant Development were administered. All examiners were blind to treatment group.

Results. Groups were similar in terms of birth weight, gestational age, gender, and race. A higher percentage of dexamethasone recipients had major intracranial abnormalities diagnosed by ultrasonography (21% vs 11%). Group differences were not found for Bayley Mental Development Index (median [range] for dexamethasone-treated group, 94 [50–123]; for placebo group, 90 [28–117]) or Psychomotor Development Index Index (median [range]) for dexamethasone-treated group, 78 (50–109); for placebo-treated group, 81 [28–117]). More dexamethasone-treated infants had cerebral palsy (25% vs 7%) and abnormal neurologic examination findings (45% vs 16%). In stratified analyses, adjusted for major cranial ultrasound abnormalities, these associations persisted (OR values for cerebral palsy, 5.3; 95% CI: 1.3–21.4; OR values for neurologic abnormality 3.6; 95% CI: 1.2–11.0).

Conclusions. A 42-day tapering course of dexamethasone was associated with an increased risk of cerebral palsy. Possible explanations include an adverse effect of this therapy on brain development and/or improved survival of infants who either already have neurologic injury or who are at increased risk for such injury.

  • bronchopulmonary dysplasia
  • dexamethasone
  • chronic lung disease
  • very low birth weight
  • randomized controlled trials
  • developmental outcome
  • cerebral palsy
  • Received April 21, 1998.
  • Accepted November 19, 1998.
  • Copyright © 1999 American Academy of Pediatrics

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 104, Issue 1
1 Jul 1999
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age
T. Michael O'Shea, Jamanadas M. Kothadia, Kurt L. Klinepeter, Donald J. Goldstein, Barbara G. Jackson, R. Grey Weaver, III‡; and Robert G. Dillard
Pediatrics Jul 1999, 104 (1) 15-21; DOI: 10.1542/peds.104.1.15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Randomized Placebo-controlled Trial of a 42-Day Tapering Course of Dexamethasone to Reduce the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Outcome of Study Participants at 1-Year Adjusted Age
T. Michael O'Shea, Jamanadas M. Kothadia, Kurt L. Klinepeter, Donald J. Goldstein, Barbara G. Jackson, R. Grey Weaver, III‡; and Robert G. Dillard
Pediatrics Jul 1999, 104 (1) 15-21; DOI: 10.1542/peds.104.1.15
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Hypotension in Neonates
  • Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby
  • Postnatal intravenous steroids and long-term neurological outcome: recommendations from meta-analyses
  • Adjunctive Oral Methylprednisolone in Pediatric Acute Pyelonephritis Alleviates Renal Scarring
  • Minidex: very low dose dexamethasone (0.05 mg/kg/day) in chronic lung disease
  • Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?
  • Open-Label Glucocorticoids Modulate Dexamethasone Trial Results in Preterm Infants
  • Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia
  • Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year
  • Time-Related Changes in Steroid Use and Bronchopulmonary Dysplasia in Preterm Infants
  • The Association of Lung Disease With Cerebral White Matter Abnormalities in Preterm Infants
  • Impact of Postnatal Corticosteroid Use on Neurodevelopment at 18 to 22 Months' Adjusted Age: Effects of Dose, Timing, and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants
  • Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials
  • Effects of Neonatal Dexamethasone Treatment on the Cardiovascular Stress Response of Children at School Age
  • Effects of Higher Versus Lower Dexamethasone Doses on Pulmonary and Neurodevelopmental Sequelae in Preterm Infants at Risk for Chronic Lung Disease: A Meta-analysis
  • Neonatal Dexamethasone Treatment for Chronic Lung Disease of Prematurity Alters the Hypothalamus-Pituitary-Adrenal Axis and Immune System Activity at School Age
  • Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants Exposed Prenatally to Dexamethasone Versus Betamethasone
  • Outcomes of Extremely Low Birth Weight (<1 kg) and Extremely Low Gestational Age (<28 Weeks) Infants With Bronchopulmonary Dysplasia: Effects of Practice Changes in 2000 to 2003
  • Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up
  • Follow-up of a Randomized, Placebo-Controlled Trial of Dexamethasone to Decrease the Duration of Ventilator Dependency in Very Low Birth Weight Infants: Neurodevelopmental Outcomes at 4 to 11 Years of Age
  • Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?
  • Outcome at 2 Years of Age of Infants From the DART Study: A Multicenter, International, Randomized, Controlled Trial of Low-Dose Dexamethasonef
  • Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants
  • Changes in the Use of Postnatal Steroids for Bronchopulmonary Dysplasia in 3 Large Neonatal Networks
  • Follow-up of a Randomized, Placebo-Controlled Trial of Postnatal Dexamethasone: Blood Pressure and Anthropometric Measurements at School Age
  • Neurodevelopmental and Respiratory Follow-up Results at 7 Years for Children From the United Kingdom and Ireland Enrolled in a Randomized Trial of Early and Late Postnatal Corticosteroid Treatment, Systemic and Inhaled (the Open Study of Early Corticosteroid Treatment)
  • CONTRARY TO ADULT, NEONATAL RATS SHOW PRONOUNCED BRAIN UPTAKE OF CORTICOSTEROIDS
  • Reopening the Debate on Corticosteroids: To the Editor
  • Adverse Neonatal Outcomes Associated With Antenatal Dexamethasone Versus Antenatal Betamethasone
  • Growth in the Neonatal Intensive Care Unit Influences Neurodevelopmental and Growth Outcomes of Extremely Low Birth Weight Infants
  • A Double-Blind, Randomized, Controlled Study of a "Stress Dose" of Hydrocortisone for Rescue Treatment of Refractory Hypotension in Preterm Infants
  • Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial
  • Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia
  • Structural and Functional Brain Development After Hydrocortisone Treatment for Neonatal Chronic Lung Disease
  • Executive Summary of the Workshop on the Border of Viability
  • Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease
  • Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era
  • Postnatal steroid treatment and brain development
  • Neonatologists are using much less dexamethasone
  • Maternal Glucocorticoid Supplementation and S100B Protein Concentrations in Cord Blood and Urine of Preterm Infants
  • Nutritional State and Growth and Functional Maturation of the Brain in Extremely Low Birth Weight Infants
  • Evaluation and Development of Potentially Better Practices to Prevent Chronic Lung Disease and Reduce Lung Injury in Neonates
  • Implementing Potentially Better Practices to Improve Neonatal Outcomes After Reducing Postnatal Dexamethasone Use in Infants Born Between 501 and 1250 Grams
  • Evaluation and Development of Potentially Better Practices for the Prevention of Brain Hemorrhage and Ischemic Brain Injury in Very Low Birth Weight Infants
  • Implementing Potentially Better Practices to Reduce Lung Injury in Neonates
  • Concern About Fetus and Newborn Committee Statement on Corticosteroid Use
  • Association of Antenatal and Postnatal Dexamethasone Exposure With Outcomes in Extremely Low Birth Weight Neonates
  • A three year follow up of preterm infants after moderately early treatment with dexamethasone
  • Premature Conclusions on Postnatal Steroid Effects
  • Controlled Trial of Early Dexamethasone Treatment for the Prevention of Chronic Lung Disease in Preterm Infants: A 3-Year Follow-up
  • Meta-analysis of Postnatal Steroid Use Challenged
  • Measurement of the subarachnoid space by ultrasound in preterm infants
  • Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease
  • Postnatal Corticosteroids to Treat or Prevent Chronic Lung Disease in Preterm Infants
  • Postnatal Dexamethasone for Bronchopulmonary Dysplasia: A Systematic Review and Meta-analysis of 20 Years of Clinical Trials
  • A Randomized Trial of Moderately Early Low-Dose Dexamethasone Therapy in Very Low Birth Weight Infants: Dynamic Pulmonary Mechanics, Oxygenation, and Ventilation
  • Review: early postnatal corticosteroids reduce chronic lung disease in preterm infants, but increase complications
  • Review: moderately early postnatal corticosteroids reduce chronic lung disease and mortality in preterm infants, but increase complications
  • Neurobehavioral Deficits in Premature Graduates of Intensive Care--Potential Medical and Neonatal Environmental Risk Factors
  • The Role of Follow-up in Randomized Controlled Trials
  • Hazards of systemic steroids for ventilator-dependent preterm infants: What would a parent want?
  • Postnatal Glucocorticoids in Very Preterm Infants: "The Good, the Bad, and the Ugly"?
  • A Multicenter, Randomized Open Study of Early Corticosteroid Treatment (OSECT) in Preterm Infants With Respiratory Illness: Comparison of Early and Late Treatment and of Dexamethasone and Inhaled Budesonide
  • Impaired Cerebral Cortical Gray Matter Growth After Treatment With Dexamethasone for Neonatal Chronic Lung Disease
  • Demographic and Therapeutic Determinants of Pain Reactivity in Very Low Birth Weight Neonates at 32 Weeks' Postconceptional Age
  • Early postnatal dexamethasone treatment and increased incidence of cerebral palsy
  • Antenatal steroids and the developing brain
  • A 42 day tapering course of dexamethasone reduced duration of assisted ventilation in very low birthweight infants, but increased risk of cerebral palsy at age 1 year
  • Early Dexamethasone--Attempting To Prevent Chronic Lung Disease
  • Google Scholar

More in this TOC Section

  • Nurse Home Visiting and Maternal Mental Health: 3-Year Follow-Up of a Randomized Trial
  • Neighborhood Child Opportunity Index and Adolescent Cardiometabolic Risk
  • Neonates Born to Mothers With COVID-19: Data From the Spanish Society of Neonatology Registry
Show more Article

Similar Articles

Keywords

  • bronchopulmonary dysplasia
  • dexamethasone
  • chronic lung disease
  • very low birth weight
  • randomized controlled trials
  • developmental outcome
  • cerebral palsy
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics